← FDA DRUG APPROVALS

FDA ANDA · ANDA078347

HALOPERIDOL LACTATE

Sponsor: MYLAN LABS LTD

APPLICATION
ANDA078347
TYPE
ANDA
ORIGINAL APPROVAL
2009-09-14
LATEST ACTION
2025-01-22
ROUTE
INTRAMUSCULAR, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

HALOPERIDOLPrescription
HALOPERIDOL LACTATE EQ 5MG BASE/ML · INJECTABLE · INJECTION

Approval history

2025-01-22Labeling · Supplement 22 · standardAP
2025-01-16Labeling · Supplement 16 · standardAP
2019-10-09Labeling · Supplement 13 · standardAP
2018-06-08Labeling · Supplement 8 · standardAP
2018-06-08Labeling · Supplement 11 · standardAP
2018-06-08Labeling · Supplement 7 · standardAP
2010-12-03Labeling · Supplement 1AP
2009-09-14OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →